Bupropion 150 Mg & 300 Mg XR Dyna Tablet

BUPROPION XR DYNA is indicated for the treatment of depression as defined by DSM IV Criteria. Following a satisfactory response, continuation with BUPROPION XR Dyna therapy is effective in preventing relapse and preventing recurrence of further depressive episodes.

Therapy should be initiated by medical practitioners experienced in the treatment of depression.

Posology: Initial treatment: The initial dose of BUPROPION XR DYNA is 150 mg taken as a single daily dose in the morning. Patients who are not responding adequately to a dose of 150 mg/day may benefit from an increase to the usual adult target dose of 300 mg/day, given once daily. There should be an interval of at least 24 hours between successive doses. Insomnia is a very common adverse event which is often transient. Insomnia may be reduced by avoiding dosing at bedtime (provided there is at least 24 hours between doses) or, if clinically indicated, dose reduction.

Switching Patients from sustained release tablets: When switching patients from sustained release tablets to extended release tablets; give the same total daily dose when possible. Patients who are currently being treated with sustained release tablets at 300 mg/day (e.g. 150 mg twice daily) may be switched to extended release tablets 300 mg once daily.

Special populations

• Elderly: Greater sensitivity of some elderly individuals to BUPROPION XR DYNA cannot be ruled out, hence a reduced frequency and/or dose may be required (see section 4.4).
• Renal Impairment: Treatment of patients with renal impairment should be initiated at a reduced frequency and/or dose, as BUPROPION XR DYNA and its metabolites may accumulate in such patients to a greater extent than usual (see section 4.4).
• Liver Impairment: BUPROPION XR DYNA should be used with caution in patients with mild liver impairment. Because of increased variability in the pharmacokinetics in patients with mild hepatic cirrhosis, a reduced frequency of dosing should be considered (see sections 4.4 and 4.8), BUPROPION XR DYNA is contraindicated in patients with moderate to severe hepatic cirrhosis.
• Paediatric population: BUPROPION XR DYNA is not indicated for use in children or adolescents aged less than 18 years (see section 4.3).

Method of administration: BUPROPION XR DYNA tablets should be swallowed whole. The tablets should not be cut, crushed or chewed as this may lead to an increased risk of adverse effects including seizures.

• hypersensitivity to BUPROPION XR DYNA or to any of the excipients listed in 6.1
• patients under 18 years
• BUPROPION XR DYNA is contraindicated in patients with a seizure disorder
• BUPROPION XR DYNA should not be administered to patients currently being treated with any other preparation containing bupropion, as the incidence of seizures is dose dependent
• BUPROPION XR DYNA is contraindicated in patients undergoing abrupt discontinuation of alcohol or sedatives
• BUPROPION XR DYNA is contraindicated in patients with a current or previous diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was seen in this patient population when BUPROPION XR DYNA was administered
• concomitant administration of BUPROPION XR DYNA with monoamine oxidase inhibitors (MAOIs) is contraindicated. At least 14 days should elapse between the discontinuation of MAOIs and initiation of treatment with BUPROPION XR DYNA
• liver disease, Child-Pugh grades B and C, range 7-13.

Seizures: The recommended dose of BUPROPION XR DYNA should not be exceeded, since bupropion is associated with a dose-related risk of seizure. BUPROPION XR DYNA should be discontinued promptly if patients experience hypersensitivity reactions during treatment (see section 4.8). Medical practitioners should be aware that symptoms may persist beyond the discontinuation of BUPROPION XR DYNA and clinical management should be provided accordingly. The overall incidence of seizure with bupropion hydrochloride in clinical trials was approximately 0.1%. There is an increased risk of seizures occurring with the use of BUPROPION XR DYNA in the presence of predisposing risk factors, which lower the seizure threshold. Therefore, BUPROPION XR DYNA should not be administered to patients with one or more conditions predisposing to a lowered seizure threshold, which include:

• history of head trauma
• central nervous system (CNS) tumour
• history of seizures
• concomitant administration of other medications known to lower the seizure threshold
• excessive use of alcohol or sedatives (see section 4.3), diabetes treated with hypoglycaemics or insulin and use of stimulants or anorectic medicines.

BUPROPION XR DYNA should be discontinued and not recommenced in patients who experience a seizure while on treatment.

Clinical worsening and suicide risk in adults associated with psychiatric disorders: Patients with major depressive disorder may experience worsening of their depression and or the emergence of suicidal ideation and behaviour, whether or not they are taking antidepressant medicines. This risk may persist until significant remission occurs. A casual role, however, for antidepressant medicine in inducing such behaviour has not been established. As improvement may occur during the first few weeks or more of treatment, patients being treated with BUPROPION XR DYNA should, nevertheless, be observed closely for clinical worsening (including development of new symptoms) and suicidality, especially at the beginning of a course of therapy or at any time of dose changes, either increases or decreases. Patients with a history of suicidal behaviour or thoughts, young adults and those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment are at a greater risk of suicidal thoughts or suicide attempts and should receive careful monitoring during treatment.

The following symptoms have been reported in patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and non-psychiatric: anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness, impulsivity, akathisia, hypomania, and mania. In addition, a meta-analysis of placebo controlled clinical trials of antidepressant medicines in adults with major depressive disorder and other psychiatric disorders showed an increased risk of suicidal thinking and behaviour associated with antidepressant use compared to placebo in patients less than 25 years old. Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of their condition (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. It should be recognised that the onset of neuropsychiatric symptoms could be related either to the underlying disease state or the medicine therapy and an appropriate patient assessment should be undertaken (see section 4.8). Consideration should be given to changing the therapeutic regimen, including possibly discontinuing BUPROPION XR DYNA, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Although there is no need to taper BUPROPION XR DYNA upon discontinuation, the patient should be monitored for worsening of depressive symptoms following discontinuation.

Neuropsychiatric symptoms including mania and bipolar disorder: Neuropsychiatric symptoms have been reported (see section 4.8). In particular, psychotic and manic symptomatology has been observed, mainly in patients with a known history of psychiatric illness. Aggression, rage and violent behaviour may occur. Additionally, a major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone can increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Limited clinical data on use of BUPROPION XR DYNA in combination with mood stabilisers in patients with a history of bipolar disorder suggests a low rate of switch to mania. Prior to initiating treatment with BUPROPION XR DYNA, patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

Hepatic impairment: BUPROPION XR DYNA is extensively metabolised in the liver to active metabolites, which are further metabolised. No statistically significant differences in the pharmacokinetics of bupropion were observed in patients with mild hepatic cirrhosis compared with healthy volunteers, but bupropion plasma levels showed a higher variability between individual patients. Therefore, BUPROPION XR DYNA should be used with caution in patients with mild hepatic impairment and reduced frequency of dosing should be considered (see sections 4.3 and 5.2).

Renal impairment and elderly patients: Bupropion is extensively metabolised in the liver to active metabolites which are further metabolised and excreted by the kidneys. Therefore, treatment of patients with renal impairment should be initiated at reduced frequency and/or dose as bupropion and its metabolites may accumulate in such patients to a greater extent than usual. The patient should be closely monitored for possible adverse effects (e.g. insomnia, dry mouth, seizures) that could indicate high bupropion or metabolite levels, toxic effects of elevated blood and tissue levels of bupropion and metabolites. Clinical experience with BUPROPION XR DYNA has not identified any differences in tolerability between elderly and other adult patients, However, greater sensitivity of some elderly individuals cannot be ruled out, hence a reduced frequency and/or dose may be required (see section 5.2).

Cardiovascular disease: There is limited clinical experience of the use of BUPROPION XR DYNA to treat depression in patients with cardiovascular disease. A causal relationship between the use of BUPROPION XR DYNA and sudden death cannot be excluded. Care should be exercised if BUPROPION XR DYNA is used in these patients.

Children and Adolescents <18 years: The safety and efficacy with the treatment of BUPROPION XR DYNA tablets in patients under 18 years of age have not been established. Treatment with antidepressants is associated with an increased risk of suicidal thinking and behaviour in children and adolescents with major depressive disorder and other psychiatric disorders (see section 4.3).

Medicines known to affect the CYP2B6 isoenzyme: Bupropion is metabolised to its major active metabolite hydroxybupropion primarily by the cytochrome P450 IIB6 (CYP2B6) (see section 5.2). Care should therefore be exercised when BUPROPION XR DYNA is co-administered with medicines known to affect the CYP2B6 isoenzyme (e.g. orphenadrine, cyclophosphamide, ifosfamide, ticlopidine, clopidogrel).

Medicines metabolized by CYP2D6: Although bupropion is not metabolised by the CYP2D6 isoenzyme, in vitro human P450 studies have shown that bupropion and hydroxybupropion are inhibitors of the CYP2D6 pathway. In a human pharmacokinetic study, administration of bupropion increased plasma levels of desipramine. This effect was present for at least 7 days after the last dose of bupropion. Concomitant therapy with medicines predominantly metabolised by this isoenzyme (such as certain beta-blockers, anti-dysrhythmics, selective serotonin re-uptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), antipsychotics should be initiated at the lower end of the dose range of the concomitant medicine. If BUPROPION XR DYNA is added to the treatment regimen of a patient already receiving a medication metabolised by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index (see section 5.2.).

Citalopram: Although citalopram is not primarily metabolised by CYP2D6, in one study, bupropion increased the C max and AUC of citalopram by 30% and 40%, respectively.

Medicines known to induce metabolism: Since bupropion is extensively metabolised, the co-administration of medicines known to induce metabolism (e.g. carbamazepine, phenobarbitone, phenytoin) or inhibit metabolism may affect its clinical activity.

Ritonavir: In a series of studies in healthy volunteers, ritonavir (100 mg twice daily or 600 mg twice daily) or ritonavir 100 mg plus lopinavir 400 mg twice daily reduced the exposure of bupropion and its major metabolites in a dose dependent manner by approximately 20 to 80%. This effect is thought to be due to the induction of bupropion metabolism. Patients receiving ritonavir may need increased doses of BUPROPION XR DYNA but the maximum recommended dose of BUPROPION XR DYNA should not be exceeded.

Alcohol: There have been reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients drinking alcohol during bupropion hydrochloride treatment. The consumption of alcohol during BUPROPION XR DYNA treatment should be minimised or avoided.

Levodopa or amantadine: Limited clinical data suggest a higher incidence of adverse events in patients receiving concurrent administration of bupropion and levodopa. Administration of BUPROPION XR DYNA to patients receiving either levodopa or amantadine concurrently should be undertaken with caution.

Nicotine: Concomitant use of BUPROPION XR DYNA and a Nicotine Transdermal System (NTS) may result in elevations of blood pressure.

Monoamine oxidase inhibitors (MAOIs): Bupropion inhibits the reuptake of dopamine and norepinephrine. Concomitant use of monoamine oxidase inhibitors (MAOIs) and bupropion is contraindicated because there is an increased risk of hypertensive reactions if bupropion is used concomitantly with MAOIs. At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of treatment with BUPROPION XR DYNA. Conversely, at least 14 days should be allowed after stopping BUPROPION XR DYNA before starting an MAOI antidepressant. Bupropion has been classified as possibly porphyrinogenic. It should be used only when no safe alternative is available, and precautions should be considered in vulnerable patients.

Safety in pregnancy and lactation has not been established.

Pregnancy: Epidemiological studies of pregnancy outcomes following maternal exposure to bupropion in the first trimester have reported an association with increased risk of some congenital cardiovascular malformations, including ventricular septal defects and left ventricular outflow tract defects. These findings are not consistent across studies.

Breastfeeding: As bupropion and its metabolites are excreted in human breast milk, mothers should be advised not to breastfeed while taking BUPROPION XR DYNA.

Fertility: There is no data on fertility with BUPROPION XR DYNA.

Patients should exercise caution before driving or use of machinery until they are reasonably certain BUPROPION XR DYNA tablets do not adversely affect their performance.

Tabulated list of adverse effects

System Organ Class Frequency Side effects

Blood and lymphatic system disorders Frequency unknown Ecchymosis, anaemia, leukocytosis, leukopenia, lymphadenopathy, pancytopenia, and thrombocytopenia, altered PT and/or INR, associated with haemorrhagic or thrombotic complications, when co-administered with warfarin

Immune system disorders Frequent Less frequent Hypersensitivity reactions such as urticaria More severe hypersensitivity reactions including angioedema, dyspnoea/bronchospasm and anaphylactic shock, arthralgia, myalgia, fever, rash (symptoms resemble serum sickness)

Endocrine disorders Frequency unknown Hyperglycaemia, hypoglycaemia, syndrome of inappropriate antidiuretic hormone secretion

Metabolism and nutrition disorders Frequent Less frequent Frequency unknown Anorexia, weight loss Blood glucose disturbances Glycosuria

Psychiatric disorders Frequent Less frequent Frequency unknown Insomnia, agitation, anxiety Confusion, depression, aggression, hostility, irritability, restlessness, hallucinations, abnormal dreams, depersonalisation, delusions, paranoid ideation Suicide attempt

Nervous system disorders Frequent Less frequent Frequency unknown Headache, tremor, dizziness, taste disorders Concentration disturbances, seizures (see section 4.4), dystonia, ataxia, parkinsonism, incoordination, memory impairment, paraesthesia, syncope Emotional lability, derealization, euphoria, abnormal coordination, hyperkinesia, hypertonia, hyperesthesia, vertigo, amnesia, abnormal electroencephalogram (EEG), akinesia, aphasia, coma, dysarthria, dyskinesia, extrapyramidal syndrome, hypokinesia, increased libido, neuralgia, neuropathy, unmasking tardive dyskinesia

Eye disorders Frequent Frequency unknown Visual disturbance Accommodation abnormality, dry eye, increased intraocular pressure angle-closure glaucoma, mydriasis

Ear and labyrinth disorders Frequent Frequency unknown Tinnitus Deafness

Cardiac disorders Less frequent Frequency unknown Tachycardia, palpitations complete atrioventricular block, extrasystoles, myocardial infarction

Vascular disorders Frequent Less frequent Frequency unknown Increased blood pressure (sometimes severe), flushing Vasodilation, postural hypotension Hypertension, stroke, phlebitis, pulmonary embolism

Respiratory, thoracic and mediastinal disorders Frequency unknown Bronchospasm, pneumonia

Gastrointestinal disorders Frequent Frequency unknown Dry mouth, gastrointestinal disturbance including nausea and vomiting, abdominal pain, constipation Gastric reflux, stomatitis, thirst, colitis, esophagitis, gastrointestinal haemorrhage, intestinal perforation, stomach ulcer

Hepato-biliary disorders Less frequent Frequency unknown Elevated liver enzymes, jaundice, hepatitis Abnormal liver function, liver damage, pancreatitis

Skin and subcutaneous tissue disorders Frequent Less frequent Frequency unknown Rash, pruritus, sweating Erythema multiforme and Stevens-Johnson syndrome Maculopapular rash, alopecia, angioedema, exfoliative dermatitis and hirsutism

Musculoskeletal, connective tissue and bone disorders Less frequent Frequency unknown Twitching Leg cramps, fever/rhabdomyolysis, and muscle weakness

Renal and urinary disorders Less frequent Frequency unknown Urinary frequency and/or retention Dysuria, urinary incontinence, cystitis

Reproductive system and breast disorders Frequency unknown Impotence, prostate disorder, abnormal ejaculation, dyspareunia, gynaecomastia, menopause, painful erection, salpingitis, vaginitis

General disorders and administrative site conditions Frequent Frequency unknown Fever, asthenia, chest pain. Bruxism, gingivitis, glossitis, increased salivation, mouth ulcers, oedema of tongue, gum haemorrhage

Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions to SAHPRA via the online service for adverse drug reaction reporting by following the link: https://www.sahpra.org.za/Publications/Index/8. An email can be sent directly to the company, [email protected] to ensure safety of the product.

Signs and symptoms: Drowsiness, loss of consciousness and ECG changes such as conduction disturbances (including QRS prolongation) or dysrhythmias. Acute ingestion of doses in excess of 10 times the maximum therapeutic dose has been reported.

Management of overdose: In the event of overdose, hospitalisation is advised. ECG and vital signs should be monitored. Ensure an adequate airway, oxygenation and ventilation. The use of activated charcoal is recommended. No specific antidote for bupropion is known. Further management should be as clinically indicated or as recommended by the national poisons centre, where available.